Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.46 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.36 |
| ▸ | AMD1 | P17707 | 5/20 | 0.35 |
| ▸ | NT5E | P21589 | 4/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | CD99 | P14209 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13855566 | 0.92 | ADORA3 (0.43) | ADORA3HSPA8ADORA2AADORA1AMD1 | |
| SCHEMBL13855567 | 0.82 | ADORA3 (0.61) | ADORA3HSPA8ADORA2AADORA1AMD1 | |
| SCHEMBL3880012 | 0.81 | ADORA3 (0.70) | ADORA3ADORA2AADORA1NT5EPDE2A | |
| SCHEMBL13855570 | 0.78 | ADORA3 (0.33) | ADORA3AMD1NT5ECD99 | |
| SCHEMBL13855564 | 0.76 | ADORA3 (0.33) | ADORA3 | |
| SCHEMBL5034818 | 0.70 | HSPA8 (0.55) | ADORA3HSPA8ADORA2AADORA1AMD1 | |
| SCHEMBL5034807 | 0.70 | HSPA8 (0.55) | ADORA3HSPA8ADORA2AADORA1AMD1 | |
| SCHEMBL14075810 | 0.70 | HSPA8 (0.55) | ADORA3HSPA8ADORA2AADORA1AMD1 | |
| SCHEMBL13855563 | 0.68 | ADORA3 (0.39) | ADORA3ADORA2AADORA1AMD1NT5E | |
| SCHEMBL13102225 | 0.65 | HSPA8 (0.74) | HSPA8AMD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118220-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118220-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | HPRT1, APRT, NUDT1 | ADORA3 34/4885HSPA8 4053/4885ADORA2A 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.